<DOC>
	<DOCNO>NCT03025022</DOCNO>
	<brief_summary>The objective study evaluate absorption , distribution , metabolism , excretion ( ADME ) 14C-JNJ-42847922 healthy subject single oral dose 40 milligram ( mg ) 14C-JNJ-42847922 contain maximally 100 MicroCurie . Safety tolerability also assess .</brief_summary>
	<brief_title>A Study Investigate Absorption , Distribution , Metabolism , Excretion 14C-JNJ-42847922 After Single Oral Dose 40 mg Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent document indicating ( healthy participant ) understand purpose procedure require study willing participate study Willing adhere prohibition restriction specify protocol Women may eligible participate non childbearing potential , define ( ) Postmenopausal : A postmenopausal state define menses 12 month without alternative medical cause . A high follicle stimulate hormone ( FSH ) level ( [ &gt; ] 40 International Units Per Litre [ IU/L ] milliInternational Units per milliliter [ mIU/mL ] ) postmenopausal range may use confirm postmenopausal state woman use hormonal contraception hormonal replacement therapy , however absence 12 month amenorrhea , single FSH measurement insufficient ; OR ( b ) Permanently Sterile : Permanent sterilization method include hysterectomy , bilateral salpingectomy , bilateral tubal occlusion/ligation procedure , bilateral oophorectomy Body mass index ( BMI ; weight kilogram [ kg ] /height^2 ( meter [ ] ^2 ) ) 18 30 kilogram per meter square ( kg/m^2 ) ( inclusive ) , body weight less 50 kg ( kilogram ) Blood pressure ( participant supine 5 minute ) 90 140 millimeter Merury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic screen Day 1 A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function , include : Sinus rhythm , Pulse rate 45 90 beat per minute ( bpm ) , correct QT ( QTc ) interval less equal ( &lt; = ) 450 millisecond ( msec ) , QRS interval &lt; 110 msec , PR interval le ( &lt; ) 200 msec . Morphology consistent healthy cardiac conduction function . During study minimum 1 spermatogenesis cycle ( define approximately 90 day ) receive last dose study drug , addition user independent highly effective method contraception , man sexually active woman childbearing potential must agree use barrier method contraception ( example [ e.g . ] , condom spermicidal foam/gel/film/cream/suppository ) must agree donate sperm , pregnant must use condom . Nontobacco user ( nicotine substance , include tobacco product ( e.g. , cigarette , ecigarettes , cigar , chew tobacco , gum patch ) ( current past 6 month prior screen ) Exposure significant radiation professional medical reason except dental xrays ( example , serial xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) within 12 month prior dose . Exposure Xrays thorax bone skeleton , ( exclude spinal column ) past 12 month Participants participate radiolabelled drug study 12 month prior dose History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , syncope , hypotension , hypertension vascular disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency ( creatinine clearance 60 milliLiter per minute ( mL/min ) , kidney urinary tract disturbance , thyroid disease , neurologic disease , significant psychiatric disorder , epilepsy , fit unexplained blackout , infection , illness investigator considers exclude participant could interfere interpretation study result Has history malignancy within 5 year screen ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy , opinion investigator , concurrence Sponsor 's Medical Monitor , consider cure minimal risk recurrence ) Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen ( 325 milligram [ mg ] ) , within 14 day first dose study drug schedule completion study Received know inhibitor cytochrome P450 ( CYP ) 3A4 CYP2C9 activity within 28 day period le 5 time drug 's half life ( t1/2 ) , whichever longer , dose study drug schedule completion study Received known inducer CYP3A4 CYP2C9 activity within 28 day dose study drug schedule completion study Consumption grapefruit product within 28 day first dose study drug schedule completion study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's half life ( t1/2 ) , whichever longer , dose study drug schedule History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 1 year screen positive test result ( ) alcohol , cotinine , and/or drug abuse ( hallucinogen , barbiturate , opiate , opioids , cocaine , cannabinoids , amphetamine , benzodiazepine ) screen Day 1 treatment period Known allergy study drug excipients formulation Donated blood blood product substantial loss blood ( 500 milliLitre [ mL ] ) within 3 month first administration study drug intention donate blood blood product study If man , plan father child enrol study 3 month receive last dose study drug Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody Regular use tobacco nicotine containing product past 6 month , determine medical history participant 's verbal report Positive test result ( ) nicotine screen Day 1 treatment period Recent change bowel habit ( frequency , consistency , amount ) irregular defecation pattern ( le one defecation per day ) Preplanned surgery procedure would interfere conduct study Employee investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator employee Johnson &amp; Johnson Any participant , opinion Investigator , participate study Has suicidal ideation intent act , per Columbia Suicide Severity Rating Scale ( CSSRS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>